QuidelOrtho Q4 revenue $743M (-14% YoY); GAAP EPS $0.10, adj. EPS $1.17; FY24 guidance issued

QuidelOrtho Corp

2023-FY EPS reported -$0.15 revenue$2,997,800,000

Q4 revenue $743M vs $867M YoY; non-respiratory +9%, respiratory -49%.
GAAP diluted EPS $0.10 (prior $0.45); adjusted diluted EPS $1.17 (prior $1.76).
Full-year 2023 revenue $3.0B; GAAP diluted loss $0.15; adjusted EBITDA $723M (24% margin).
FY24 guidance: revenue $2.76-3.07B; adj. EBITDA $565-720M; adj. EPS $2.40-3.07.
Received 510(k) for Savanna multiplex platform and CLIA waiver for Sofia 2 SARS Antigen+ FIA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

QuidelOrtho Corp updated its fourth quarter and full-year ended December 31, 2023 guidance (initiated).

Period: fourth quarter and full-year ended December 31, 2023
Guidance: initiated
Result: reported results

Exact text from the filing

On February 13, 2024, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its fourth quarter and full year ended December 31, 2023 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on February 13, 2024 to discuss such results.

View on SEC.gov

Browse all earnings releases →

QuidelOrtho Corp filing history →

Source: SEC EDGAR

accession 0001906324-24-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.